Use of comparative effectiveness research for similar Chinese patent medicine for angina pectoris of coronary heart disease: a new approach based on patient-important outcomesReportar como inadecuado

Use of comparative effectiveness research for similar Chinese patent medicine for angina pectoris of coronary heart disease: a new approach based on patient-important outcomes - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.


, 15:84

First Online: 19 March 2014Received: 08 November 2013Accepted: 24 February 2014DOI: 10.1186-1745-6215-15-84

Cite this article as: Cao, H., Zhai, J., Mu, W. et al. Trials 2014 15: 84. doi:10.1186-1745-6215-15-84


BackgroundThe practice of traditional Chinese medicine TCM has a profound history in many Asian countries. TCM syndrome is a set of characteristic physical signs and symptoms shared by a group of patients. Syndrome diagnosis and treatment assignment according to the identified TCM syndrome is a long-held practice of Chinese medicine. Owing to its distinctive way of interpreting illness and administering care, medical practitioners not well educated in TCM theories and practices are generally incapable of giving out prescriptions for Chinese patent drugs. Currently, the existence of a multitude of Chinese patent drugs marked with largely identical indications is further complicating this situation.

MethodsIn this multicenter, randomized, controlled, double-blind, double-dummy clinical trial, in which we will use the comparative effectiveness research method, we will compare the efficacy of two commonly used Chinese patent medicines for angina patients diagnosed with qi deficiency and blood stasis syndrome. A total of 160 patients will be recruited and randomly assigned to receive either 1 QiShenYiQi dripping pills, Tongxinluo placebo and routine medication or 2 Tongxinluo capsules, QiShenYiQi placebo and routine medication. These treatment regimens will be carried out for 4 weeks, followed by a 10-day washout period and a 4-week crossover phase in which the treatments in the two patient groups will be exchanged. Patients will be allowed to choose symptoms that matter most to them and will be grouped accordingly. Patient-reported outcomes such as the Seattle Angina Questionnaire score and the 15-point Likert scale score will be measured and reported. The minimally clinical important difference will be calculated and used for efficacy assessment, and correspondence analysis will be performed to identify the best indications for each drug.

DiscussionThe goal of the study is to establish a methodology for the precise identification of the characteristic indications for which a Chinese patent drug is most effective. The findings of this study will inform the practicality of the proposed evaluation method.

Trial registrationChinese clinical trials register Chi CTRTTRCC13003732

KeywordsAngina pectoris Chinese patent medicine Comparative effectiveness research Patient-important outcomes Electronic supplementary materialThe online version of this article doi:10.1186-1745-6215-15-84 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Hongbo Cao - Jingbo Zhai - Wei Mu - Xiang Lei - Hongxia Cao - Chunxiang Liu - Hongcai Shang


Documentos relacionados